Clinical trials: Alveolar Lung Disease
Lung Diseases, Mechanical Ventilation
Mitochondrial Dysfunction of Alveolar and Circulating Immune Cells During Acute Respiratory Distress Syndrome: Impact of Infectious Aggression and Alveolar Stretching as a Result of Mechanical Ventilation.
Sepsis leads to a deregulated host response that can lead to organ failure. During sepsis, experimental and clinical data suggest the occurrence of mitochondrial dysfunctions, particularly in circulating muscle and monocytes…
- Conditions
- Lung Diseases, Mechanical Ventilation, Bronchoalveolar Lavage
- Trial name
- PNEUMOCHONDRIE (NCT03955887)
- Testing
- bronchoalveolar lavage fluid (BAL), Venous blood
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Sleep Apnea Syndromes in Children, Obesity in Children
Overview: Use of Respiratory Support At Home in Children
the primary outcome is to describe the perceived success of the use of the respiratory support from the parent's point of view
- Conditions
- Sleep Apnea Syndromes in Children, Obesity in Children, Bronchopulmonary Dysplasia (BPD), Neuromuscular Disease
- Trial name
- ELIPSE (NCT06692660)
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Grenoble
Lung Diseases, Respiratory Distress Syndrome, Newborn
Epidemiology of Surfactant Protein-B Deficiency
The purpose of this study is to test the hypothesis that excess, rare, functionally disruptive single nucleotide polymorphisms (SNPs) characterize genes (e.g., the surfactant protein-B gene)(SFTPB) and gene networks (e.g., the…
- Conditions
- Lung Diseases, Respiratory Distress Syndrome, Newborn, Pulmonary Surfactant, Lung Diseases, Interstitial
- Trial name
- NCT00014859
- Where
- United States
- Volunteers
- 5,176 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Sars-CoV2, Innate Immunity
Immune Cells Phenotypes During COVID-19
The ongoing pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) has infected more than one hundred twenty million peoples worldwide one year after its onset with a case-fatality rate of almost 2%.
- Conditions
- Sars-CoV2, Innate Immunity, Immunization; Infection, Alveolar Lung Disease
- Trial name
- IMMUNO-COVID (NCT04816760)
- Testing
- Peripheral blood samples
- Where
- 2 sites in France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Institut Hospitalo-Universitaire Méditerranée Infection
COVID-19, Virus; Pneumonia
PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients
COVID-19 originated from Severe Acut Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection leads to critical condition due to hypoxemic respiratory failure with the background of viral pneumonia.
- Conditions
- COVID-19, Virus; Pneumonia, Atelectasis
- Trial name
- NCT04360837
- Testing
- alveolar recruitment
- Where
- Hungary
- Volunteers
- 2 people
- Sponsor
- Szeged University
Lung Neoplasms, Non-Small Cell Lung Cancer
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene
Current chemotherapy for advanced non-small cell lung cancer, not amenable for curative local treatment (surgery or chemoradiotherapy), has a modest life-prolonging effect and can improve quality of life.
- Conditions
- Lung Neoplasms, Non-Small Cell Lung Cancer, Adenocarcinoma, Bronchiolo-Alveolar
- Trial name
- NCT00339586
- Testing
- Erlotinib
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Universitair Ziekenhuis Brussel
Pulmonary Alveolar Proteinosis, Primary Disease
Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis
The purpose of this study is to determine whether the use of rituximab is effective in treating pulmonary alveolar proteinosis by leading to an improvement in lung function and disease status.
- Trial name
- PAP (NCT00552461)
- Testing
- rituximab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- East Carolina University
Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
Background: Healthy people have white blood cells that protect them against bacteria, viruses, and fungi. However, some people have diseases which cause the body to make white blood cells that do not work properly.
- Trial name
- NCT01842386
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Long COVID, Breathlessness
Long COVID and Post-exertional Pulmonary Diffusion
Aim of investigators was to study whether abnormalities of lung diffusing capacity for nitric oxide (DLNO) and carbon monoxide (DLCO) in long COVID may have a clinical impact in relation to exercise intolerance.
- Conditions
- Long COVID, Breathlessness, Exercise Intolerance, Alveolar Lung Disease
- Trial name
- Long_COVID_Ex (NCT05430503)
- Testing
- Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise
- Where
- Italy
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Alveolar Recruitment Maneuvers, Atelectasis
Alveolar Recruitment Maneuvers on Reduction of Lung Atelectasis in Bariatric Surgery by Using Lung Ultrasound Score
The study aims to compare the staircase alveolar recruitment maneuver with PEEP titration versus sustained inflation alveolar recruitment maneuver by using lung ultrasound score as an indicator of improving lung atelectasis in…
- Conditions
- Alveolar Recruitment Maneuvers, Atelectasis, Bariatric Surgery
- Trial name
- NCT05720351
- Testing
- Lachmann maneuver, Staircase maneuver
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
Covid19
Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).
Hypothesis: The apelin/APJ system is involved in the protection of the lung affected by the COVID-19 by interacting with the SARS-coV-2 entry door: the Angiotensin I Converting Enzyme 2 (ACE2) and the renin-angiotensin system…
- Trial name
- APEL-COVID (NCT04632732)
- Testing
- COVID-19 test, Blood sampling
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Asthma
Zileuton and Exhaled Nitric Oxide in Asthmatics
Evaluate the additive role of zileuton 600mg qid to clinically stable asthmatics on Advair 250/50 bid. Since asthma is an endogenous inflammatory disease there usually is increased total exhaled, bronchial and alveolar nitric…
- Trial name
- NCT00575861
- Testing
- zileuton
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Gelb, Arthur F., M.D.
Lung Cancer
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00553462
- Testing
- carboplatin, erlotinib hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 99 sites in United States
- Volunteers
- 78 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Interstitial Lung Diseases
Nanoparticles Analysis in Lung and Bronchi During Various Pulmonary Interstitial Diseases and Relationships With Their Aetiology
Nanoparticles (NP) are particles whose length, width and height are less than 100 nanometres. Over the past decade, industrial applications of NP have increased dramatically.
- Trial name
- NANOPI (NCT02549248)
- Testing
- BAL, BW, EAC
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Lung Cancer
Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving Gefitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be…
- Trial name
- NCT00616499
- Testing
- gefitinib, neoadjuvant therapy, therapeutic conventional surgery
- Where
- 4 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- Yonsei University
Lung Cancer
Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01024712
- Testing
- carboplatin, gefitinib, paclitaxel
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
IDIOPATHIC PULMONARY FIBROSIS
The Role of Gastric Content Microaspirations in the Pathogenesis of Idiopathic Pulmonary Fibrosis
The pathogenesis of idiopathic pulmonary fibrosis (IPF) is debatable. Looking for an insult to lung parenchyma that generates the pathogenesis of the disease is challenging.
- Trial name
- NCT01714934
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Lung Cancer, Adenocarcinoma
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime)…
- Trial name
- NCT00430261
- Testing
- sunitinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Swedish Medical Center
Atelectasis, Postoperative Pulmonary
Oxygen Concentration During Alveolar Recruitment
The purpose of this study is to investigate the effect of oxygen concentration during alveolar recruitment on absorption ateletasis.
- Trial name
- NCT03943433
- Testing
- FiO2_1.0, FiO2_0.4
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Seoul National University Hospital
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00368992
- Testing
- cetuximab, paclitaxel, bevacizumab
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)